Immune Resistance and Anti-Tumor Immunity in the Ovarian Tumor Microenvironment
4 affiliations
- 1Department of Medicine, Cardinal Bernardin Cancer Center, Stritch School of Medicine, Loyola University Chicago, Building 112, 2160 South First Avenue, Maywood, IL 60153, USA
- 2Division of Hematology, Oncology and Palliative Care, UW School of Medicine and Public Health, University of Wisconsin (UW) Carbone Cancer Center, 600 N. Highland Avenue, K4/530, Madison, WI 53792, USA
- 3Department of Obstetrics and Gynecology, Cardinal Bernardin Cancer Center, Loyola University Chicago, 2160 South First Avenue, Maywood, IL 60153, USA
- 4Department of Radiation Oncology, Cardinal Bernardin Cancer Center, Loyola University Chicago, 2160 South First Avenue, Maywood, IL 60153, USA
Abstract
Ovarian cancer is a lethal gynecologic malignancy with limited effective treatment options. It is expected that in 2026 there will be about 21,010 new cases of ovarian cancer diagnosed and about 12,450 deaths within the United States. Unfortunately, conventional therapies such as chemotherapy and radiation have limited efficacy for high-grade serous ovarian cancer (HGSOC) and also produce significant toxicity. HGSOC is characterized by an ovarian tumor microenvironment (TME) consisting of immune inhibitory T regulatory cells and inhibitory tumor-associated macrophages, including myeloid-derived suppressor cells (MDSCs) and M2 cells, which confer immune suppression. Immunocompetent T cells, tumor-suppressing M1 cells, natural killer cells, and other cellular subsets are also present. The TME is further shaped by soluble molecules, extracellular matrix, and other structural components, as well as the presence of blood vessels and ascitic fluid in the peritoneal cavity, which aid in the distribution of cancer cells to the omentum where more lesions soon develop. This review outlines the heterogenous immune cell subsets in the ovarian TME and other structural targets that promote or reduce cancer burden. Most single-agent immune strategies have shown limited efficacy in unselected HGSOC populations due to the complex immune-suppressive nature of the TME. Here, we also discuss novel combination treatments in clinical trials or in clinical practice for HGSOC. Advances in understanding the ovarian TME will reveal new immunotherapy and drug targets for translational medicine and aid in determining effective drug and immunotherapy combinations, which may ultimately lead to improved overall survival in HGSOC.
Related
- Patient-derived ascites reveals functional advantages of γδCAR T-cells within the ovarian cancer-like tumor microenvironment
- In situ hydrogel nanovaccine based on whole-cell tumor antigen efficiently activates adaptive immunity for the prevention and treatment of ovarian cancer
- Editorial: Preclinical models and emerging technologies to study the effects of the tumor microenvironment on cancer heterogeneity and drug resistance
- HMGB1 expression in CT26 murine cancer cells modulates the tumor microenvironment and limits local anti-tumor immunity
- Macrophage- or neutrophil-expressed UPP1 drives tumor growth and immune suppression in the tumor microenvironment
BibTeX
@article{stiff2026immune,
title = {{Immune Resistance and Anti-Tumor Immunity in the Ovarian Tumor Microenvironment}},
author = {Patrick J. Stiff and Cheryl M. Czerlanis and Ronald K. Potkul and William Small and Maureen L. Drakes},
journal = {Cells},
year = {2026},
month = nov,
doi = {10.3390/cells15212004},
url = {https://www.mdpi.com/2073-4409/15/21/2004},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Immune Resistance and Anti-Tumor Immunity in the Ovarian Tumor Microenvironment
AU - Patrick J. Stiff
AU - Cheryl M. Czerlanis
AU - Ronald K. Potkul
AU - William Small
AU - Maureen L. Drakes
PY - 2026
DA - 2026/11/03
JO - Cells
DO - 10.3390/cells15212004
UR - https://www.mdpi.com/2073-4409/15/21/2004
AB - Ovarian cancer is a lethal gynecologic malignancy with limited effective treatment options. It is expected that in 2026 there will be about 21,010 new cases of ovarian cancer diagnosed and about 12,450 deaths within the United States. Unfortunately, conventional therapies such as chemotherapy and radiation have limited efficacy for high-grade serous ovarian cancer (HGSOC) and also produce significant toxicity. HGSOC is characterized by an ovarian tumor microenvironment (TME) consisting of immune inhibitory T regulatory cells and inhibitory tumor-associated macrophages, including myeloid-derived suppressor cells (MDSCs) and M2 cells, which confer immune suppression. Immunocompetent T cells, tumor-suppressing M1 cells, natural killer cells, and other cellular subsets are also present. The TME is further shaped by soluble molecules, extracellular matrix, and other structural components, as well as the presence of blood vessels and ascitic fluid in the peritoneal cavity, which aid in the distribution of cancer cells to the omentum where more lesions soon develop. This review outlines the heterogenous immune cell subsets in the ovarian TME and other structural targets that promote or reduce cancer burden. Most single-agent immune strategies have shown limited efficacy in unselected HGSOC populations due to the complex immune-suppressive nature of the TME. Here, we also discuss novel combination treatments in clinical trials or in clinical practice for HGSOC. Advances in understanding the ovarian TME will reveal new immunotherapy and drug targets for translational medicine and aid in determining effective drug and immunotherapy combinations, which may ultimately lead to improved overall survival in HGSOC.
SN - 2073-4409
ER -